BCHT(SH:688276)2025-01-23 09:25Financial Performance - The company expects a net profit attributable to shareholders for 2024 to be between 200 million to 240 million yuan, a decrease of 26.1 million to 30.1 million yuan compared to the previous year, representing a decline of 52.10% to 60.08%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 197.79 million to 237.79 million yuan, down by 25.56 million to 29.56 million yuan year-on-year, indicating a decrease of 51.80% to 59.91%[3] - The total profit for the previous year was 563.76 million yuan, with a net profit attributable to shareholders of 501.01 million yuan[4] Market Challenges - The company faced a significant decline in sales and usage of the herpes zoster vaccine due to reduced public vaccination willingness and decreased market demand[6] Research and Development - The company has made progress in multiple research pipelines, including the acceptance of the marketing authorization application for the nasal spray influenza vaccine and ongoing clinical trials for various monoclonal antibodies[8] - The company is advancing several clinical research projects, including the rabies vaccine and respiratory syncytial virus vaccine, to strengthen its product structure and core competitiveness[9] Marketing Strategies - The company is enhancing its marketing system and increasing public awareness efforts to stimulate user demand and improve market share[9]